Publication stageIn Press Journal Pre-Proof
Joscha Vonderlin conceived, designed and wrote the manuscript. Triantafyllos Chavakis and Michael Sieweke provided intellectual input and edited the manuscript. Frank Tacke contributed to the conception, provided intellectual input and edited the manuscript
Potential conflict of interest: FT’s lab received research grants from Gilead, Allergan, Bristol-Myers Squibb and Inventiva.
Sources of funding: This work was funded by the German Research Foundation (CRC1382, Project-ID 403224013, and SFB/TRR 296) and the German Ministry of Education and Research (BMBF DEEP-HCC consortium).
Acknowledgment: Figures were created with BioRender
Distinct macrophage populations are key drivers in promoting but also in attenuating disease progression during all states of NAFLD pathogenesis, making them an attractive therapeutic target. This review provides an overview of the broad spectrum of functionally diverse macrophage phenotypes in NAFLD and related systemic metabolic diseases. The focus was placed on pathogenic relationships and mechanistic interactions of different macrophage populations, as well as on possible therapeutic approaches targeting their (mal)function.
User licenseCreative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) |
For non-commercial purposes:
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article (private use only, not for distribution)
- Reuse portions or extracts from the article in other works
- Sell or re-use for commercial purposes
- Distribute translations or adaptations of the article
Elsevier's open access license policy